Table 1.
SUCRA (%) of various interventions.
| Interventions | HbA1c | Patients achieving HbA1c < 7% | FPG | 2h PPG | BW | BMI | Hypoglycemia | GIAEs | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | |
| Placebo | 0.57 | 9 | 0.33 | 6 | 15.37 | 8 | 14.20 | 7 | 96.67 | 1 | 53.35 | 2 | 48.22 | 4 | 93.75 | 1 |
| Bromocriptine 0.8 mg | 16.18 | 8 | NA | NA | 0.38 | 9 | 1.93 | 8 | NA | NA | 70.87 | 1 | 80.82 | 1 | 0.15 | 3 |
| Metformin 500 mg | 57.48 | 5 | NA | NA | 57.45 | 4 | 48.07 | 6 | NA | NA | NA | NA | NA | NA | NA | NA |
| Vildagliptin 100 mg | 64.41 | 3 | NA | NA | 43.29 | 7 | 56.11 | 5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Sitagliptin 100 mg | 61.30 | 4 | 77.85 | 2 | 73.50 | 2 | 79.06 | 1 | 18.25 | 3 | 31.48 | 4 | 42.70 | 5 | NA | NA |
| Teneligliptin 5 mg | 33.66 | 7 | 34.33 | 5 | 51.45 | 6 | NA | NA | NA | NA | NA | NA | 51.44 | 3 | NA | NA |
| Teneligliptin 10 mg | 55.21 | 6 | 43.60 | 4 | 54.80 | 5 | 60.25 | 4 | NA | NA | NA | NA | 75.66 | 2 | NA | NA |
| Teneligliptin 20 mg | 75.67 | 2 | 58.07 | 3 | 69.53 | 3 | 61.28 | 3 | 35.07 | 2 | 44.31 | 3 | 32.82 | 6 | 56.11 | 2 |
| Teneligliptin 40 mg | 85.51 | 1 | 85.81 | 1 | 84.24 | 1 | 79.06 | 2 | NA | NA | NA | NA | 18.35 | 7 | NA | NA |
The doses of all the antidiabetic drugs are daily dose. SUCRA, the surface under the cumulative ranking curve value; FPG, fasting plasma glucose; 2h PPG, 2 h postprandial plasma glucose; BW, body weight; BMI, body mass index; GIAEs, gastrointestinal adverse events; NA, not available.